Dear Colleagues,

Cancer is the second leading cause of death in the pediatric population, with leukemia and brain tumors being the two most common malignancies. Recent treatment advances have led to significant improvements in survival. However, the severity of the underlying malignancy and the use of increasingly aggressive therapeutic regimens can cause organ toxicity with both short-term and long-term consequences. Close collaboration between nephrologists, oncologists, pharmacists, dieticians, endocrinologists, transplant providers, intensivists, and infectious disease experts is critical to maximize outcomes for these complicated patients. Though my interest and expertise is in kidney injury after cancer and HSCT and our understanding of the mechanisms of kidney injury has allowed the field of onconephrology to grow, continued research in this area and other organ toxicities including, lung, heart, endocrine, reproductive, brain, and gastrointestinal will hopefully further improve outcomes for patients in the future. As more patients are surviving longer, multidisciplinary survivorship clinics are increasingly following those treated for cancer or having received a HSCT.

For this special edition of Current Oncology, the goal is to describe the treatment-related toxicity of cancer therapy and newer immunotherapies and approaches to management with an emphasis on prevention of both short and long-term complications with an understanding that the toxicity in one organ does not occur in isolation. This edition will hopefully serve as a reference for oncologists and primary providers to effectively manage and monitor survivors and to support the creation of multidisciplinary survivorship clinics at institutions so that comprehensive care can be delivered in one clinic. We need a more holistic approach to the care of patients with cancer that starts at the time of diagnosis.

Prof. Dr. Sangeeta R. Hingorani
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Current Oncology is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2200 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

• organ toxicity
• short and long-term outcomes
• prevention
• management
• monitoring
• epidemiology
• multidisciplinary